ICC Lowe taps Brown to lead two offices

Share this article:

Matt Brown, formerly president of inVentiv digital shop Ignite Health, has been hired by Interpublic Group's ICC Lowe to lead its main office and its medical-device division.

Brown replaces Paul O'Neill, former president of the flagship Parsippany office, ICC Lowe, who has been promoted to the new role of chief growth officer for the network, and John Friedberg, former general manager of emerging technology and device unit ICC Lowe Redshift.

Bringing Brown on board -- one of several personnel-related moves announced recently by ICC Lowe, the healthcare arm of IPG's Lowe & Partners -- increases the agencies' depth of services, said Steve Viviano, ICC Lowe CEO, in a statement.

“We took a very deliberate approach to finding a leader who could take us to the next level,” he said. “Matt…is especially attuned to the rapidly evolving face of healthcare communications.”

Brown's insight stems from having had a mix of pharma, device and technology clients at Ignite, including accounts like Endo Pharmaceuticals' pain franchise, Roche Molecular Systems, Allergan's LapBand, J&J's Depuy unit and Abbott's iLasik Impressions. The Irvine, CA-based Ignite doubled in size between 2008 and 2011, MM&M reported, and restructured in 2011.

ICC Lowe also retooled in 2011, when Lowe & Partners rebranded its global healthcare network from Lowe Healthcare Worldwide to ICC Lowe and made Viviano CEO of the new entity and its advertising and marketing units.

Since then, more agencies have been brought into the ICC Lowe fold, the network won MM&M Agency of the Year, and the shops in the global network have demonstrated the ability to work together.

Also among the most recent wave of senior-level title changes was the promotion of Margaret Anne Ingram to general manager of ICC Lowe Pace, from SVP, management supervisor. Ingram joined Pace in March from Flashpoint Medica, primarily to lead its largest US and global account, Vertex.

At the other US conflict shop, ICC Lowe Trio, Renee Wills was promoted from general manager to president. Since Wills joined the agency two years ago, Trio has doubled in size, has had very low turnover, and recently moved into larger quarters. “They're our growth engine right now,” said Viviano earlier this year.

In addition, Dr. Stacy Patterson, formerly EVP, director medical affairs and education of the flagship office, was promoted to chief medical officer for all of ICC Lowe, and O'Neill, formerly the president of the flagship office, was tapped to lead the network's global expansion effort.

O'Neill's focus will be on establishing the ICC Lowe brand in important markets around the world beginning with India, and moving to Brazil, China, Japan and beyond, said ICC Lowe. He will work with various Lowe & Partners offices to help identify appropriate healthcare offerings, on refining and formalizing the company's global process and adding new services, either by building organically or bringing them on through acquisition.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...